Horizon Therapeutics PLC $ 72.41 -0.24 (-0.33%)
On watch
Volume:
1,321,713
Avg Vol (1m):
2,901,051
Market Cap $:
15.96 Bil
Enterprise Value $:
16.40 Bil
P/E (TTM):
29.68
P/B:
6.12
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.62 | ||
| Equity-to-Asset | 0.52 | ||
| Debt-to-Equity | 0.5 | ||
| Debt-to-EBITDA | 3.6 | ||
| Interest Coverage | 1.7 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 4.72 | ||
| Beneish M-Score | -1.8 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 8.21 | ||
| Net Margin % | 34.09 | ||
| ROE % | 26.37 | ||
| ROA % | 12.49 | ||
| ROC (Joel Greenblatt) % | 82.05 | ||
| 3-Year Revenue Growth Rate | 1.2 | ||
| 3-Year EBITDA Growth Rate | 42.9 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 29.67 | ||
| PE Ratio without NRI | 29.67 | ||
| Price-to-Owner-Earnings | 528.55 | ||
| PB Ratio | 6.12 | ||
| PS Ratio | 9.88 | ||
| Price-to-Free-Cash-Flow | 110.22 | ||
| Price-to-Operating-Cash-Flow | 54.24 | ||
| EV-to-EBIT | 239.99 | ||
| EV-to-EBITDA | 50.16 | ||
| EV-to-Revenue | 10.79 | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 1.45 | ||
| Days Inventory | 54.85 | ||
| Days Sales Outstanding | 130.77 | ||
| Days Payable | 95.83 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 249.69 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 3.02 | ||
| Price-to-Graham-Number | 18.29 | ||
| Earnings Yield (Greenblatt) % | 0.42 |